Drosera rotundifolia (Sundew)

Drosera rotundifolia, commonly called sundew, is a carnivorous plant whose bioactive naphthoquinones — primarily plumbagin and 7-methyljuglone — drive its medicinal activity. These compounds inhibit phosphodiesterase enzymes PDE1A and PDE4D in airway smooth muscle, producing antispasmodic and mucociliary-supporting effects relevant to respiratory conditions.

Origin & History

Drosera rotundifolia (round-leaved sundew) is a carnivorous perennial herb native to peatlands and bogs across Europe, North America, and Asia. The medicinal preparation uses dried aerial parts (Droserae Herba), typically extracted with ethanol or water to yield extracts rich in flavonoids and naphthoquinones.

Historical & Cultural Context

Drosera rotundifolia has been used in European phytotherapy and homeopathy for centuries to treat respiratory diseases, coughs, and pulmonary conditions. The dried aerial parts (Droserae Herba) are accepted in various pharmacopeias, with therapeutic effects traditionally attributed to its flavonoid and naphthoquinone content.

Health Benefits

• May support respiratory health by stimulating bronchial epithelial cell function and increasing ciliary beat frequency (preliminary in vitro/ex vivo evidence only)
• Demonstrates antispasmodic effects on airway smooth muscle through PDE1A/PDE4D inhibition (ex vivo murine studies)
• Shows antiviral activity against coxsackieviruses CVA9/CVB3 at 1-10% concentrations (in vitro evidence, p<0.0001)
• Inhibits biofilm formation in multidrug-resistant E. coli (in vitro 3D mucosa models)
• Exhibits anti-inflammatory effects at 500 μg/pellet doses (in ovo HET-CAM assay)

How It Works

Drosera's naphthoquinone constituents, particularly plumbagin and 7-methyljuglone, inhibit cyclic nucleotide phosphodiesterases PDE1A and PDE4D in bronchial smooth muscle, elevating intracellular cAMP and cGMP levels to produce bronchodilation and antispasmodic effects. Separately, these compounds stimulate bronchial epithelial ciliary beat frequency in ex vivo models, suggesting a mucociliary clearance mechanism independent of adrenergic pathways. Antiviral activity has been attributed to naphthoquinone-mediated disruption of viral replication machinery, though the precise molecular targets in human pathogens remain under investigation.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified for Drosera rotundifolia. Available evidence is limited to preclinical in vitro studies on human bronchial epithelial cells (16HBE line) and ex vivo murine airway studies, plus antimicrobial assays on cell cultures and 3D mucosa models.

Clinical Summary

Clinical evidence for Drosera rotundifolia is largely limited to traditional use documentation, ex vivo murine airway studies, and in vitro cell assays, without large-scale randomized controlled trials in humans. Ex vivo studies on murine tracheal preparations demonstrated measurable reductions in carbachol-induced smooth muscle contraction attributable to PDE inhibition. The ESCOP monograph recognizes Drosera for use in dry, spasmodic, and irritating coughs based on a combination of pharmacological plausibility and longstanding European herbal tradition, rather than robust Phase II or Phase III clinical data. Practitioners and consumers should interpret current evidence as preliminary, supporting plausibility rather than confirmed clinical efficacy.

Nutritional Profile

Drosera rotundifolia is a carnivorous botanical used medicinally rather than as a conventional food source; macronutrient content (carbohydrates, protein, fat) is not nutritionally significant at therapeutic doses. Key bioactive compounds include: Naphthoquinones — plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone, estimated 0.1–1.2% dry weight) and 7-methyljuglone, considered primary pharmacologically active constituents; Flavonoids — quercetin, kaempferol, and hyperoside (quercetin-3-galactoside), with hyperoside reported at approximately 0.5–2.0 mg/g dry weight in some aerial part extracts; Phenolic acids — ellagic acid, gallic acid, and chlorogenic acid present in measurable but variable concentrations depending on harvest conditions; Proteolytic enzymes — digestive proteases (e.g., plumbase) concentrated in leaf glands, functionally active but not nutritionally relevant at medicinal doses; Tannins — ellagitannins and gallotannins contributing astringent properties, estimated 3–8% dry weight; Mucilages — polysaccharide-based mucilaginous secretions in glandular tentacles; Minerals — trace calcium, potassium, and magnesium absorbed from prey, concentrations highly variable and not standardized. Bioavailability note: Plumbagin demonstrates moderate oral bioavailability with lipophilic character (LogP ~1.6) facilitating membrane permeation; flavonoid glycosides require intestinal hydrolysis prior to absorption. Standardized extracts are typically characterized by plumbagin or total naphthoquinone content. Vitamin content is negligible at therapeutic doses.

Preparation & Dosage

No clinically studied human dosage ranges exist. In vitro studies used 1000-fold diluted ethanolic extracts (3× homeopathic dilution) for 3-6 hours on cell cultures, and 1-10% extract concentrations for antiviral effects. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Thyme, Ivy leaf, Marshmallow root, Elderberry, Echinacea

Safety & Interactions

Drosera rotundifolia is generally considered well-tolerated at traditional herbal doses, with no serious adverse events documented in published literature at typical therapeutic amounts, though systematic safety trials in humans are lacking. The naphthoquinone plumbagin exhibits cytotoxic properties in high-concentration in vitro models, raising theoretical concern about long-term or high-dose use that has not been evaluated in human pharmacokinetic studies. Potential interactions with phosphodiesterase inhibitor medications (e.g., theophylline, sildenafil) are theoretically plausible given shared mechanisms, warranting caution in patients on these drugs. Use during pregnancy and lactation is not recommended due to insufficient safety data, consistent with ESCOP guidance.